REG - Oxford Biomedica PLC - Oxford Biomedica Signs Agreement with Arcellx

Oxford BioMedicaAnnouncement

13/12/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211213:nRSM3584Va&default-theme=true

RNS Number : 3584V  Oxford Biomedica PLC  13 December 2021

 

 

Oxford Biomedica Signs Licence & Supply Agreement with Arcellx, Inc. for
LentiVector(®) Platform for CAR-T Therapeutics

Oxford, UK - 13 December 2021: Oxford Biomedica plc (LSE:OXB) ("Oxford
Biomedica" or "the Group"), a leading gene and cell therapy group, today
announces that it has signed a new Licence and Supply Agreement ("LSA") with
Arcellx, Inc. ("Arcellx"), a Gaithersburg MD.-based biotechnology company
developing novel, adaptive and controllable cell therapies for the treatment
of patients with cancer and autoimmune diseases. The LSA grants Arcellx a
non-exclusive licence to Oxford Biomedica's LentiVector(®) platform for its
application in select Arcellx CAR-T programmes and puts in place a three-year
Clinical Supply Agreement.

Under the terms of the LSA, Oxford Biomedica will receive payments related to
the development and manufacturing of lentiviral vectors for use in clinical
trials. Additionally, the agreement allows for payments to the Group for the
manufacture and supply of lentiviral vectors for commercial use.

This partnership with a leader in the CAR-T field builds on the longstanding
partnerships with Novartis and Bristol Myers Squibb, as well as the more
recently announced partnership with Beam Therapeutics.

John Dawson, Chief Executive Officer of Oxford Biomedica, said: "Arcellx is
one of the leading next-generation CAR-T developers deploying a wide range of
innovative technologies to bring innovative CAR-T products into development.
We are proud to be working with a leader in the field of CAR-T that shares our
vision of delivering cell and gene therapies to save lives. This is yet
another valuable opportunity for our LentiVector(®) platform to support
innovative product development of CAR-T products further highlighting Oxford
Biomedica's position as a partner of choice."

Rami Elghandour, Chairman and CEO of Arcellx said: "We look forward to
leveraging Oxford Biomedica's renowned LentiVector(®) platform technology,
and their industry-leading development and GMP manufacturing expertise in the
clinical and commercial development of our CAR-T programmes."

 

 

-Ends-

 

Enquiries:

 

Oxford Biomedica plc: T: +44 (0)1865 783 000 / E: ir@oxb.com

 

John Dawson, Chief Executive Officer

Stuart Paynter, Chief Financial Officer

Sophia Bolhassan, Head of Investor Relations

 

Consilium Strategic Communications: T: +44 (0)20 3709 5700

 

Mary-Jane Elliott / Matthew Neal

 

 

 

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell
therapy group focused on developing life changing treatments for serious
diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a
sector leading lentiviral vector delivery platform (LentiVector®), which the
Group leverages to develop in vivo and ex vivo products both in-house and with
partners. The Group has created a valuable proprietary portfolio of gene and
cell therapy product candidates in the areas of oncology, CNS disorders and
liver diseases. The Group has also entered into a number of partnerships,
including with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard
Therapeutics, Santen, Beam Therapeutics and Boehringer Ingelheim, through
which it has long-term economic interests in other potential gene and cell
therapy products. Additionally, the Group has signed a 3-year master supply
and development agreement with AstraZeneca for large-scale manufacturing of
the adenoviral based COVID-19 vaccine candidate, AZD1222. Oxford Biomedica is
based across several locations in Oxfordshire, UK and employs more than 740
people. Further information is available at www.oxb.com (http://www.oxb.com)

 

About Arcellx, Inc.

Arcellx is a clinical-stage biopharmaceutical company developing adaptive and
controllable cell therapies for the treatment of patients with cancer and
autoimmune diseases. The Arcellx vision is to utilize our novel proprietary
platform to bring superior cell therapies to more patients through the care of
academic and community practices worldwide. More information can be found
at www.arcellx.com (http://www.arcellx.com/) .

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGRBLLLFFLLFFBD